Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Company to host a virtual webinar on PRMT5 data and the synthetic lethality pipeline, including WRN and novel target discovery, today Monday, October 16 at 9.30 am CEST Presentations include updated data from the lead preclinical program on MTA-cooperative PRMT5 inhibitors Preclinical…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.